메뉴 건너뛰기




Volumn 27, Issue 3, 2009, Pages 167-175

Variations in c-Myc and p21WAF1 expression protect normal peripheral blood lymphocytes against BimEL-mediated cell death

Author keywords

Apoptosis; BimEL; c Myc; P21Waf1; Peripheral blood lymphocyte; SAHA; Vorinostat

Indexed keywords

BCL2 RELATED PROTEIN A1; BETA ACTIN; BIM PROTEIN; BONE MORPHOGENETIC PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; MYC PROTEIN; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN BID; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; VORINOSTAT; X LINKED INHIBITOR OF APOPTOSIS;

EID: 65549171638     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.1552     Document Type: Article
Times cited : (4)

References (34)
  • 1
    • 35548988945 scopus 로고    scopus 로고
    • Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) 2007; 43: 585-599.
    • Duvic M, Vu J. Vorinostat in cutaneous T-cell lymphoma. Drugs Today (Barc) 2007; 43: 585-599.
  • 2
    • 34547683194 scopus 로고    scopus 로고
    • Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
    • Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007; 25: 3109-3115.
    • (2007) J Clin Oncol , vol.25 , pp. 3109-3115
    • Olsen, E.A.1    Kim, Y.H.2    Kuzel, T.M.3
  • 3
    • 38949096781 scopus 로고    scopus 로고
    • Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes
    • Garcia-Manero G, Yang H, Bueso-Ramos C, et al. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes. Blood 2008; 111: 1060-1066.
    • (2008) Blood , vol.111 , pp. 1060-1066
    • Garcia-Manero, G.1    Yang, H.2    Bueso-Ramos, C.3
  • 4
    • 65549084884 scopus 로고    scopus 로고
    • http://clinicaltrials.gov/ct2/results?term=saha
  • 5
    • 33644836549 scopus 로고    scopus 로고
    • Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies
    • O'Connor OA, Heaney ML, Schwartz L, et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J Clin Oncol 2006; 24: 166-173.
    • (2006) J Clin Oncol , vol.24 , pp. 166-173
    • O'Connor, O.A.1    Heaney, M.L.2    Schwartz, L.3
  • 6
    • 39749103428 scopus 로고    scopus 로고
    • Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma
    • Richardson P, Mitsiades C, Colson K, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma. Leuk Lymphoma 2008; 49: 502-507.
    • (2008) Leuk Lymphoma , vol.49 , pp. 502-507
    • Richardson, P.1    Mitsiades, C.2    Colson, K.3
  • 7
    • 34248325147 scopus 로고    scopus 로고
    • Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma
    • Venturelli S, Armeanu S, Pathil A, et al. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 2007; 109: 2132-2141.
    • (2007) Cancer , vol.109 , pp. 2132-2141
    • Venturelli, S.1    Armeanu, S.2    Pathil, A.3
  • 8
    • 43049092663 scopus 로고    scopus 로고
    • Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma
    • Crump M, Coiffier B, Jacobsen ED, et al. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol 2008; 19(5): 964-969.
    • (2008) Ann Oncol , vol.19 , Issue.5 , pp. 964-969
    • Crump, M.1    Coiffier, B.2    Jacobsen, E.D.3
  • 9
    • 43049091153 scopus 로고    scopus 로고
    • A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study
    • Modesitt SC, Sill M, Hoffman JS, Bender DP. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2008; 109(2): 182-186.
    • (2008) Gynecol Oncol , vol.109 , Issue.2 , pp. 182-186
    • Modesitt, S.C.1    Sill, M.2    Hoffman, J.S.3    Bender, D.P.4
  • 10
    • 36048958965 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Overview and perspectives
    • Dokmanovic M, Clarke C, Marks PA. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007; 5: 981-989.
    • (2007) Mol Cancer Res , vol.5 , pp. 981-989
    • Dokmanovic, M.1    Clarke, C.2    Marks, P.A.3
  • 11
    • 15544383986 scopus 로고    scopus 로고
    • A mechanistic approach to anticancer therapy: Targeting the cell cycle with histone deacetylase inhibitors
    • Mork CN, Faller DV, Spanjaard RA. A mechanistic approach to anticancer therapy: targeting the cell cycle with histone deacetylase inhibitors. Curr Pharm Des 2005; 11: 1091-1104.
    • (2005) Curr Pharm Des , vol.11 , pp. 1091-1104
    • Mork, C.N.1    Faller, D.V.2    Spanjaard, R.A.3
  • 12
    • 33845514708 scopus 로고    scopus 로고
    • Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds?
    • Karagiannis TC, El-Osta A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 2007; 21: 61-65.
    • (2007) Leukemia , vol.21 , pp. 61-65
    • Karagiannis, T.C.1    El-Osta, A.2
  • 13
    • 34547864236 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Molecular mechanisms of action
    • Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007; 26: 5541-5552.
    • (2007) Oncogene , vol.26 , pp. 5541-5552
    • Xu, W.S.1    Parmigiani, R.B.2    Marks, P.A.3
  • 14
    • 40849151859 scopus 로고    scopus 로고
    • Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: Role of Annexin A1
    • Petrella A, D'Acunto CW, Rodriquez M, et al. Effects of FR235222, a novel HDAC inhibitor, in proliferation and apoptosis of human leukaemia cell lines: role of Annexin A1. Eur J Cancer 2008; 44(5): 740-749.
    • (2008) Eur J Cancer , vol.44 , Issue.5 , pp. 740-749
    • Petrella, A.1    D'Acunto, C.W.2    Rodriquez, M.3
  • 15
    • 34447096461 scopus 로고    scopus 로고
    • HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway
    • Tsapis M, Lieb M, Manzo F, et al. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway. Int J Biochem Cell Biol 2007; 39: 1500-1509.
    • (2007) Int J Biochem Cell Biol , vol.39 , pp. 1500-1509
    • Tsapis, M.1    Lieb, M.2    Manzo, F.3
  • 16
    • 0035845541 scopus 로고    scopus 로고
    • The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species
    • Ruefli AA, Ausserlechner MJ, Bernhard D, et al. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001; 98: 10833-10838.
    • (2001) Proc Natl Acad Sci U S A , vol.98 , pp. 10833-10838
    • Ruefli, A.A.1    Ausserlechner, M.J.2    Bernhard, D.3
  • 17
    • 0038079767 scopus 로고    scopus 로고
    • The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1
    • Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003; 63: 3637-3645.
    • (2003) Cancer Res , vol.63 , pp. 3637-3645
    • Rosato, R.R.1    Almenara, J.A.2    Grant, S.3
  • 18
    • 33845627416 scopus 로고    scopus 로고
    • Acetylation and histone deacetylase inhibitors in cancer
    • Kortenhorst MS, Carducci MA, Shabbeer S. Acetylation and histone deacetylase inhibitors in cancer. Cell Oncol 2006; 28: 191-222.
    • (2006) Cell Oncol , vol.28 , pp. 191-222
    • Kortenhorst, M.S.1    Carducci, M.A.2    Shabbeer, S.3
  • 19
    • 46749134822 scopus 로고    scopus 로고
    • BimEL-dependent apoptosis induced in peripheral blood lymphocytes with n-butyric acid is moderated by variation in expression of c-Myc and p21WAF1
    • Kalousek I, Brodska B, Otevrelova P, Röselova P. BimEL-dependent apoptosis induced in peripheral blood lymphocytes with n-butyric acid is moderated by variation in expression of c-Myc and p21WAF1. Cell Biochem Funct 2008; 26: 509-521.
    • (2008) Cell Biochem Funct , vol.26 , pp. 509-521
    • Kalousek, I.1    Brodska, B.2    Otevrelova, P.3    Röselova, P.4
  • 20
    • 34250885082 scopus 로고    scopus 로고
    • Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes
    • Kalousek I, Brodska B, Otevrelova P, Roselova P. Actinomycin D upregulates proapoptotic protein Puma and downregulates Bcl-2 mRNA in normal peripheral blood lymphocytes. Anticancer Drugs 2007; 18: 763-772.
    • (2007) Anticancer Drugs , vol.18 , pp. 763-772
    • Kalousek, I.1    Brodska, B.2    Otevrelova, P.3    Roselova, P.4
  • 21
    • 34447521712 scopus 로고    scopus 로고
    • Impact of cellular lifespan on the T cell receptor repertoire
    • Hamrouni A, Olsson A, Wiegers GJ, Villunger A. Impact of cellular lifespan on the T cell receptor repertoire. Eur J Immunol 2007; 37: 1978-1985.
    • (2007) Eur J Immunol , vol.37 , pp. 1978-1985
    • Hamrouni, A.1    Olsson, A.2    Wiegers, G.J.3    Villunger, A.4
  • 22
    • 34447258837 scopus 로고    scopus 로고
    • Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis
    • Wojciechowski S, Tripathi P, Bourdeau T, et al. Bim/Bcl-2 balance is critical for maintaining naive and memory T cell homeostasis. J Exp Med 2007; 204: 1665-1675.
    • (2007) J Exp Med , vol.204 , pp. 1665-1675
    • Wojciechowski, S.1    Tripathi, P.2    Bourdeau, T.3
  • 23
    • 5644241900 scopus 로고    scopus 로고
    • T-lymphocyte death during shutdown of an immune response
    • Review
    • Strasser A, Pellegrini M. T-lymphocyte death during shutdown of an immune response. Trends Immunol 2004; 25: 610-615. Review.
    • (2004) Trends Immunol , vol.25 , pp. 610-615
    • Strasser, A.1    Pellegrini, M.2
  • 24
    • 33644839920 scopus 로고    scopus 로고
    • Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases
    • Review
    • Hughes P, Bouillet P, Strasser A. Role of Bim and other Bcl-2 family members in autoimmune and degenerative diseases. Curr Dir Autoimmun 2006; 9: 74-94. Review.
    • (2006) Curr Dir Autoimmun , vol.9 , pp. 74-94
    • Hughes, P.1    Bouillet, P.2    Strasser, A.3
  • 25
    • 34249993174 scopus 로고    scopus 로고
    • SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib
    • Emanuele S, Lauricella M, Carlisi D, et al. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 2007; 12: 1327-1338.
    • (2007) Apoptosis , vol.12 , pp. 1327-1338
    • Emanuele, S.1    Lauricella, M.2    Carlisi, D.3
  • 26
    • 23244459828 scopus 로고    scopus 로고
    • Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma
    • Fandy TE, Shankar S, Ross DD, Sausville E, Srivastava RK. Interactive effects of HDAC inhibitors and TRAIL on apoptosis are associated with changes in mitochondrial functions and expressions of cell cycle regulatory genes in multiple myeloma. Neoplasia 2005; 7: 646-657.
    • (2005) Neoplasia , vol.7 , pp. 646-657
    • Fandy, T.E.1    Shankar, S.2    Ross, D.D.3    Sausville, E.4    Srivastava, R.K.5
  • 27
    • 24344473755 scopus 로고    scopus 로고
    • Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2
    • Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic acid against human breast cancer cells with amplification of her-2. Clin Cancer Res 2005; 11: 6382-6389.
    • (2005) Clin Cancer Res , vol.11 , pp. 6382-6389
    • Bali, P.1    Pranpat, M.2    Swaby, R.3
  • 28
    • 38049126172 scopus 로고    scopus 로고
    • Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma
    • Heider U, von Metzler I, Kaiser M, et al. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Eur J Haematol 2008; 80: 133-142.
    • (2008) Eur J Haematol , vol.80 , pp. 133-142
    • Heider, U.1    von Metzler, I.2    Kaiser, M.3
  • 29
    • 48749090017 scopus 로고    scopus 로고
    • The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells
    • Portanova P, Russo T, Pellerito O, et al. The role of oxidative stress in apoptosis induced by the histone deacetylase inhibitor suberoylanilide hydroxamic acid in human colon adenocarcinoma HT-29 cells. Int J Oncol 2008; 33: 325-331.
    • (2008) Int J Oncol , vol.33 , pp. 325-331
    • Portanova, P.1    Russo, T.2    Pellerito, O.3
  • 30
    • 34247115447 scopus 로고    scopus 로고
    • c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression
    • Jiang X, Tsang YH, Yu Q. c-Myc overexpression sensitizes Bim-mediated Bax activation for apoptosis induced by histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through regulating Bcl-2/Bcl-xL expression. Int J Biochem Cell Biol 2007; 39: 1016-1025.
    • (2007) Int J Biochem Cell Biol , vol.39 , pp. 1016-1025
    • Jiang, X.1    Tsang, Y.H.2    Yu, Q.3
  • 31
    • 21844464054 scopus 로고    scopus 로고
    • Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis
    • Annis MG, Soucie EL, Dlugosz PJ, et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J 2005; 24: 2096-2103.
    • (2005) EMBO J , vol.24 , pp. 2096-2103
    • Annis, M.G.1    Soucie, E.L.2    Dlugosz, P.J.3
  • 32
    • 33748343207 scopus 로고    scopus 로고
    • Polyamine-modulated c-Myc expression in normal intestinal epithelial cells regulates p21Cip1 transcription through a proximal promoter region
    • Liu L, Guo X, Rao JN, et al. Polyamine-modulated c-Myc expression in normal intestinal epithelial cells regulates p21Cip1 transcription through a proximal promoter region. Biochem J 2006; 398: 257-267.
    • (2006) Biochem J , vol.398 , pp. 257-267
    • Liu, L.1    Guo, X.2    Rao, J.N.3
  • 33
    • 20144384882 scopus 로고    scopus 로고
    • Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980-3985. Review.
    • Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980-3985. Review.
  • 34
    • 0036594890 scopus 로고    scopus 로고
    • A role of the cyclin-dependent kinase inhibitor p21 in apoptosis
    • Review
    • Gartel AL, Tyner AL. A role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002; 1: 639-649. Review.
    • (2002) Mol Cancer Ther , vol.1 , pp. 639-649
    • Gartel, A.L.1    Tyner, A.L.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.